Steroid-responsive chronic inflammatory demyelinating polyradiculoneuropathy post-hematopoietic stem cell transplantation: a case report and literature review
Steroid-responsive chronic inflammatory demyelinating polyradiculoneuropathy post-hematopoietic stem cell transplantation: a case report and literature review
复制标题
造血干细胞移植后类固醇反应性慢性炎症性脱髓鞘性多发性神经根神经病一例报告及文献复习
DOI：
10.1007/s10072-021-05500-y
复制
发表时间：
2021-07
影响因子：
3.3
通讯作者：
Dong W
中科院分区：
文献类型：
--
作者：
Zhao Y;Chen X;Zhang W;Fang X;Liu X;Dong W
造血干细胞移植（HSCT）是治疗多种恶性和非恶性血液病的有效方法。在移植物抗宿主病（GVHD）的过程中，来自不匹配供体的免疫细胞将移植受体识别为外来者，从而启动针对移植受体的免疫应答，GVHD根据发病时间可分为急性和慢性[1]。急性移植物抗宿主病（aGVHD）的主要靶点是皮肤、肝脏和胃肠道[2]，而慢性移植物抗宿主病（cGVHD）可累及多个组织和器官，临床表现多样[3]，据统计，14-42%接受HSCT的患者发生神经肌肉并发症，可出现癫痫、脑病、中枢神经系统血管炎、或脱髓鞘疾病，甚至重症肌无力、肌炎和多发性周围神经病变[4-7]。以往的研究表明，只有0.2-0.3%的接受HSCT治疗的患者表现出周围神经受累。周围神经受累可表现为不对称性臂丛神经病变、急性多发性神经病变（格林-巴利综合征
Hematopoietic stem cell transplantation (HSCT) is an effective treatment for a wide variety of malignant and nonmalignant hematologic diseases. In the course of graft-versus-host disease (GVHD), immune cells from unmatched donors recognized the transplant recipient as foreigners, thereby initiated an immune response against the transplant recipient, and GVHD can be divided into acute and chronic according to the time of onset [1]. The main targets of acute GVHD (aGVHD) are skin, liver, and gastrointestinal tract [2], while chronic GVHD (cGVHD) could affect multiple tissue and organs, characterized by pleomorphic clinical manifestations [3].According to the statistics, 14–42% of patients who received HSCT developed neuromuscular complications, which could occur in the form of epilepsy, encephalopathy, central nervous system vasculitis, or demyelinating diseases, and even myasthenia gravis, myositis, and multiple peripheral neuropathies [4–7]. Previous studies indicated that only 0.2–0.3% of patients who underwent HSCT treatment showed peripheral nerve involvement. Peripheral nerve involvement could be manifested as asymmetric brachial plexus neuropathy, acute polyneuropathy (Guillain–Barre
登录
查看更多内容
DOI：
10.5692/clinicalneurol.48.426
发表时间：
2008-06
期刊：
Rinsho shinkeigaku = Clinical neurology
影响因子：
--
作者：
S. Wada;Takashi Kimura;K. Ikegame;K. Kajiyama;M. Takeda;H. Yoshikawa
通讯作者：
S. Wada;Takashi Kimura;K. Ikegame;K. Kajiyama;M. Takeda;H. Yoshikawa
影响因子：
3.4
作者：
Katherine Ruzhansky;T. Brannagan
通讯作者：
Katherine Ruzhansky;T. Brannagan
影响因子：
9.9
作者：
AMATO, AA;BAROHN, RJ;MENDELL, JR
通讯作者：
MENDELL, JR
影响因子：
4.8
作者：
H. Openshaw;D. Hinton;N. Slatkin;P. Bierman;F. Hoffman;D. Snyder
通讯作者：
H. Openshaw;D. Hinton;N. Slatkin;P. Bierman;F. Hoffman;D. Snyder
影响因子：
4.8
作者：
A. Greenspan;Deeg Hj;Michele Cottler-Fox;M. Sirdofski;Thomas R. Spitzer;J. Kattah
通讯作者：
A. Greenspan;Deeg Hj;Michele Cottler-Fox;M. Sirdofski;Thomas R. Spitzer;J. Kattah